Atypical antipsychotics and the relevance of glutamate and serotonin

European Neuropsychopharmacology

Volumn 14, Issue 3, 2004, Pages 259-265

  Van Der Heijden, F M M A ^a   Tuinier, S ^a   Fekkes, D ^b   Sijben, A E S ^a   Kahn, R S ^c   Verhoeven, W M A ^a,b  

^a VINCENT VAN GOGH INSTITUTE FOR PSYCHIATRY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Atypical antipsychotics; Glutamate; Negative symptoms; Schizophrenia; Serotonin

Indexed keywords

GLUTAMIC ACID; OLANZAPINE; QUETIAPINE; SEROTONIN; SERTINDOLE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUTAMATES; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEROTONIN; TIME FACTORS;

EID: 1642603457     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2003.09.002     Document Type: Article

References (59)

1. Aghajanian G.K., Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res. Rev. 31:2000;302-312.
2. Alfredsson G., Wiesel F.A., Tylec A. Relationships between glutamate and monoamine metabolites in cerebrospinal fluid and serum in healthy volunteers. Biol. Psychiatry. 23:1998;689-697.
3. Amin F., Davidson M., Kahn R.S., Schmeidler J., Stern R., Knott P.J., Apter S. Assessment of the central dopaminergic index of plasma HVA in schizophrenia. Schizophr. Bull. 21:1995;53-65.
4. Amin F., Silverman J.M., Siever L., Smith C.J., Knott P.J., Davis K.L. Genetic antecedents of dopamine dysfunction in schizophrenia. Biol. Psychiatry. 45:1999;1143-1150.
5. Bennett M.R. Monoaminergic synapses and schizophrenia: 4 years of neuroleptics. J. Psychopharmacol. 12:1998;289-304.
6. Bjerkenstedt L., Edman G., Hagenfeldt L., Sedvall G., Wiesel F.A. Plasma amino acid in relation tot cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br. J. Psychiatry. 147:1985;276-282.
7. Bleich A., Brown S., VanPraag H.M. A serotonin theory of schizophrenia. Brown S., Van Praag H.M. The Role of Serotonin in Psychiatric Disorders. 1991;183-214 Brunner/Mazel Publishers, New York.
8. Borgdorff P., Fekkes D., Tangelder G.J. Hypotension caused by extracorporeal circulation: serotonin from pump-activated platelets triggers nitric oxide release. Circulation. 106:2002;2588-2593.
9. Bowers M.B., Swigar M.E., Jatlow P.I., Goicoechea N. Plasma catecholamine metabolites and early response to haloperidol. J. Clin. Psychiatry. 45:1984;248-251.
10. Carlsson A. Pharmacology of synaptic monoamine transmission. Prog. Brain Res. 31:1969;53-59.
11. Castillo J., Davalos A., Noya M. Progression of ischemic stroke and excitotoxic aminoacids. Lancet. 349:1997;79-83.
12. Crow T.J., Johnstone E.C., Longden A.J., Owen F. Dopaminergic mechanisms in schizophrenia: the antipsychotic effect and the disease process. Life Sci. 23:1978;563-568.
13. Davidson M., Kahn R.S., Stern R.G.et al. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res. 46:1993;151-163.
14. Doorakkers M.C., Verhoeven W.M.A., Tuinier S., Van den Berg Y.W.M.M., Fekkes D., Pepplinkhuizen L. Psychopathology, serotonergic parameters and sertindole; results of a preliminary study in schizophrenia. New Trends Exp. Clin. Psychiatry. 17:2001;25-30.
15. Evins A., Amico E., Shih V., Goff D. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J. Neural Transm. 104:1997;761-766.
16. Faustman W.O., Bardgett M., Faull K.F., Pfefferbaum A., Csernansky J.G. Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. Biol. Psychiatry. 45:1999;68-75.
17. Fekkes D., Van Dalen A., Edelman M., Voskuilen A. Validation of the determination of amino acids in plasma by high-performance liquid chromatography using automated derivatization with o-phthaldialdehyde. J. Chromatogr., B, Biomed. Appl. 669:1995;177-186.
18. Galinowski A., Poirier M.F., Aymard N.et al. Acta Psychiatr. Scand. 97:1998;458-466.
19. Garver D.L., Holcomb J.A., Christensen J.D. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. J. Clin. Psychiatry. 61:2000;964-972.
20. Gattaz W.F., Gattaz D., Beckmann H. Glutamate in schizophrenics and healthy controls. Arch. Psychiatr. Nervenkr. 231:1982;221-225.
21. Gilbody S., Wahlbeck K., Adams C. Randomised controlled trials in schizophrenia: a critical perspective on the literature. Acta Psychiatr. Scand. 105:2002;243-251.
22. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry. 158:2001;1367-1377.
23. Goff D.C., Hennen J., Kyoon Lyoo I., Tsai G., Wald L.L., Evins A.E., Yurgelun-Todd D.A., Renshaw P.F. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol. Psychiatry. 51:2002;493-497.
24. Gray J.A., Roth B.L. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res. Bull. 56:2001;441-451.
25. Green A.I., Alam M.Y., Sobieray J.T.et al. Clozapine response and plasma catecholamines and their metabolites. Psychiatry Res. 46:1992;139-149.
26. Iqbal N., Van Praag H.M. The role of serotonin in schizophrenia. Eur. Neuropsychopharmacol. 1995;11-23.
27. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
28. Jernej B., Banovic M., Cicin-Sain L., Hranilovic D., Balija M., Oreskovic D., Folnegovic-Smalc V. Physiological characteristics of platelet/circulatory serotonin: study on large human population. Psychiatry Res. 94:2000;153-162.
29. Kahn R.S., Davidson M., Knott P., Stern R.G., Apter S., Davis K.L. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Arch. Gen. Psychiatry. 50:1993;599-605.
30. Kalkman H.O. Antischizophrenic activity independent of dopamine D2 blockade. Expert Opin. Ther. Targets. 6:2002;571-582.
31. Kelley M.E., Yao J.K., Van Kammen D.P. Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia. Neuropsychopharmacology. 20:1999;603-611.
32. Kendler K.S., Heninger G.R., Roth R.H. Influence of dopamine agonists on plasma and brain levels of homovanillic acid. Life Sci. 30:1982;2063-2069.
33. Keverne E.B. GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. Brain Res. Bull. 48:1999;467-473.
34. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal glutamate in schizophrenic patients and the new hypothesis on schizophrenia. Neurosci. Lett. 20:1980;379-382.
35. Kim Y.K., Kim L., Lee M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr. Res. 44:2000;165-175.
36. Koreen A.R., Lieberman J., Alvir J.et al. Plasma homovanillic acid levels in first-episode schizophrenia. Arch. Gen. Psychiatry. 51:1994;132-138.
37. Lieberman J.A., Kane J.M., Safferman A.Z., Pollack S., Howard A., Szymanski S., Masiar S.J., Kronig M.H., Cooper T., Novacenko H. Predictors of response to clozapine. J. Clin. Psychiatry, Suppl. 55:1994;126-128.
38. Lieberman J.A., Mailman R.B., Duncan G., Sikich L., Chakos M., Nichols D.E., Kraus J.E. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiatry. 44:1998;1099-1117.
39. Macciardi F., Lucca A., Catalano M., Marino C., Smeraldi E. Amino acid pattern in schizophrenia: some new findings. Psychiatry Res. 32:1990;63-68.
40. Malhotra A.K., Pinals D.A., Weingartner H.et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14:1996;301-307.
41. Mazure C.M., Nelson J.C., Jatlow P.I., Bowers M.B. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol. Psychiatry. 30:1991;475-482.
42. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology, Suppl. 99:1989;18-27.
43. Meltzer H.Y., Maes M., Lee M.A. The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine. Psychopharmacology, Suppl. 112:1993;95-104.
44. Mooren R., Verhoeven W.M.A., Tuinier S., Van den Berg Y.W.M.M., Fekkes D., Pepplinkhuizen L. Olanzapine in relapsing schizophrenia. Efficacy and serotonergic parameters. Eur. J. Psychiatry. 15:2001;91-100.
45. Oades R.D., Klimke A., Henning U., Rao M.L. Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia. Hum. Psychopharmacol. Clin. Exp. 17:2002;15-27.
46. Pickar D., Labarca R., Doran A.R., Wolkowitz O.M., Roy A., Breier A., Linnoila M., Paul S.M. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch. Gen. Psychiatry. 43:1986;669-676.
47. Risch S.C., Lewine R.R.J. Clozapine therapy and increases in homovanillic acid. Arch. Gen. Psychiatry. 52:1995;244.
48. Scheepers F.E., Gispen-deWied C.C., Westenberg H.G.M., Kahn R.S. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology. 25:2001;468-475.
49. Strawn J.R., Ekhator N.N., Anthenelli R.M., Baker D.G., Maxwell R.A., Hill K.K., Geracioti T.D. Intra- and inter-individual relationships between central and peripheral serotonergic activity in humans: a serial cerebrospinal fluid sampling study. Life Sci. 71:2002;1219-1225.
50. Szymanski S., Lieberman J., Pollack S., Munne R., Safferman A., Kane J., Kronig M., Cooper T. The dopamine-serotonin relationship in clozapine response. Psychopharmocology, Suppl. 112:1993;85-89.
51. Tortorella A., Monteleone P., Fabrazzo M., Viggiano A., De Luca L., Maj M. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology. 44:2001;167-171.
52. Tsai G., Van Kammen D., Chen S., Kelley M., Grier A., Coyle J. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol. Psychiatry. 44:1998;667-674.
53. Van der Heijden F.M.M.A., Verhoeven W.M.A., Fekkes D., Sijben A.E.S., Tuinier S. Quetiapine in relapsing schizophrenia: clinical efficacy and effect on monoaminergic parameters. Acta Neuropsychiatr. 15:2003;133-139.
54. Van Kammen D.P., Agren H., Yao J.K., O'Connor D.T., Gurklis J., Peters J.L. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. Am. J. Psychiatry. 151:1994;379-384.
55. Verhoeven, W.M.A., 1983. Endogenous opioids and γ-type endorphins in schizophrenia. Thesis.
56. Verhoeven W.M.A., Rijn-Van den Meijdenberg J.C.C., Hofma E., Tuinier S., Fekkes D., Pepplinkhuizen L. Amino acids, norharman and serotonergic parameters in schizophrenia: clinical and biochemical effects of treatment with risperidone. New Trends Exp. Clin. Psychiatry. 13:1997;117-126.
57. Wieselgren I.M., Lindstrom L.H. CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Psychiatry Res. 81:1998;101-110.
58. Yao J.K., VanKammen D.P., Moss H.B., Sokulski D.E. Decreased serotonergic responsivity in platelets of drug-free patients with schizophrenia. Psychiatry Res. 63:1996;123-132.
59. Zhang Z.J., Peet M., Ramchand C.N., Shah S., Reynolds G.P. Plasma homovanillic acid in untreated schizophrenia - relationship with symptomatology and sex. J. Psychiatr. Res. 35:2001;23-28.